Clinical trials: Subcutaneous Fat Disorder
- Condition Subcutaneous Fat Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hyperlipidemia
A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects
It is a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. The study plans to conduct four to six dose groups of dose 1, dose 2, dose 3, dose4, dose5 (optional), and dose 6(optional).
- Trial name
- NCT06541457
- Testing
- HRS-7249 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Body Fat Disorder
Pilot Study on the Submental Area
The purpose of this study is to evaluate the safety and feasibility of cryolipolysis for non-invasive reduction of submental fat.
- Trial name
- NCT01859091
- Testing
- The Zeltiq System
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Hypercholesterolemia and Hyperlipidemia
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety…
- Trial name
- NCT05370950
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypercholesterolemia
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
Primary Objective: To assess the effects of subcutaneous (SC) doses of alirocumab on the elimination (measured by Fractional Clearance Rate (FCR)) of apolipoprotein B (apoB) in low density lipoprotein (LDL) in adults with mildly…
- Trial name
- NCT01959971
- Testing
- alirocumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Moderate or Severe Submental Fullness
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety of deoxycholic acid subcutaneous injections in the submental area (below the chin).
- Trial name
- NCT01426373
- Testing
- Deoxycholic acid injection
- Where
- 18 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Body Fat Disorder
CoolSculpting of the Flank With Alternate Treatment Parameters
The purpose of this study is to evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction with an alternative treatment parameter.
- Trial name
- NCT02081196
- Testing
- The Zeltiq CoolSculpting System
- Where
- 3 sites in United States, Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Dyslipidemia
A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HRS-5632 Following a Single Subcutaneous Injection in Healthy Subjects
- Trial name
- NCT06732154
- Testing
- HRS-5632
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hypercholesterolemia
Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
Primary Objective: Injection Site Tolerability Secondary Objectives: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01443650
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanofi
Body Fat Disorder
Subcutaneous Fat Reduction in the Submental Area
Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area using Cryolipolysis. Healthy adult men and women with submental skin fold thickness > 1cm who desire reduction of submental fat.
- Trial name
- NCT02298322
- Testing
- CoolSculpting System
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Healthy, Hypercholesterolemia
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase
This is a Phase 1, open-label, single-dose, randomized, dose escalation study in healthy and hypercholesterolemic subjects. Each subject will receive 1 of 5 treatments as a single subcutaneous injection.
- Trial name
- NCT02667223
- Testing
- Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia, Dyslipidemias
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
This Phase 1 study has been designed to evaluate the absolute bioavailability of PF-04950615 (RN316) in subjects with hypercholesterolemia who are not currently on lipid-lowering therapy.
- Conditions
- Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders
- Trial name
- NCT01435382
- Testing
- PF-04950615 (RN316)
- Where
- 7 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia and Hyperlipidemia
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration.
- Trial name
- NCT06837077
- Testing
- SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hypercholesteremia
The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
This is a Single Center, Randomized, Double-blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics with A Single Subcutaneous Injection…
- Trial name
- NCT03634436
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Fat Disorder
Non-invasive Cooling of Subcutaneous Fat
The purpose of this study is to evaluate a non-invasive cooling device to determine if cold exposure will consistently result in a reduction of subcutaneous fat.
- Trial name
- NCT00762307
- Testing
- Zeltiq Dermal Cooling Device
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Hypercholesterolemia
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects
Primary Objective: To assess the safety and tolerability of ascending single SC doses of alirocumab in Chinese healthy subjects. Secondary Objectives: To assess the pharmacokinetic profile of a single SC dose of alirocumab.
- Trial name
- NCT02979015
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hypercholesterolemia, LDL Cholesterol
Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
This study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of LGT209 in hypercholesterolemic patients taking common statin medications and in healthy volunteers.
- Trial name
- NCT01859455
- Testing
- LGT209 50 mg, LGT209 300 mg, Statins (atorvastatin or simvastatin)
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia
Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects
Primary Objective: To assess the relative bioavailability of a single subcutaneous dose of alirocumab SAR236553 (REGN727) administered at 3 different injection sites in healthy subjects.
- Trial name
- NCT01785329
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hypercholesterolemia
Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
Primary Objective: Injection Site Tolerability Secondary Objectives: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01448239
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Moderate or Severe Submental Fullness
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- REFINE-1 (NCT01542034)
- Testing
- Deoxycholic acid injection
- Where
- 36 sites in United States, Canada
- Volunteers
- 506 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Obesity
Technical Validation of Lunar iDXA Visceral Fat Tool
The goal of this project is to compare visceral fat measurements derived from Lunar iDXA total body scans and from Computed Tomography (CT) scans of the abdominal region for a Chinese population.
- Trial name
- NCT01110161
- Testing
- Visceral fat mass measurement
- Where
- China
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GE Healthcare